One community at a time

R.J. Bischoff¹, P.R. Springer¹, N.C. Taylor¹; ¹University of Nebraska-Lincoln, Lincoln, NE, USA

Program/Project Purpose: Mental health conditions continue to be one of the leading causes of disability worldwide. This is largely because adequate mental health care is not readily accessible in many parts of the world, including in many parts of the U.S. These disparities in access to care are the result of a complex interplay between availability of mental health care providers, affordability of care, and additional factors that influence the perception and acceptability of mental health care (e.g., stigma, culture, policy). Solutions that work must address this complexity. The purpose of this program was to develop a community partnership model to reduce mental healthcare disparities that address the complexity of challenges faced by underserved communities, locally and globally.

Structure/Method/Design: Funded through a grant from the USDA, we have developed a model for reducing mental health care disparities around the world one community at a time. We used rural towns (<2500; designated as Mental Health Care Professional Shortage Areas) in the U.S. as laboratories for the mental health care disparities problem worldwide. Our innovative model emphasizes working within the local cultural context to a) build community capacity to make a difference by mobilizing existing resources, b) collaborate with local medical providers, and c) determine sustainable ways to increase access and acceptability to mental health care (including telemental health).

Outcome & Evaluation: Through the collection of qualitative and quantitative data from patients, medical providers, and staff at end-user sites, we evaluated the feasibility of the model. Five years after its implementation, we interviewed members of the communities in which the model was used to determine principles that facilitated sustainability. Key findings of both the feasibility and sustainability study will be presented.

Going Forward: The application of this model has implications for addressing global mental health disparities. We have increased the scale of the project globally as we are implementing the model in Brazil and are in discussions with other global partners in Portugal and Australia; demonstrating how local solutions can have global impact.

Funding: USDA Challenge Grant (2009).

Hepatitis C Treatment Outcomes in Kigali, Rwanda

S. Taylor¹, R. Simango¹, Y. Ogolu¹, R. Riel¹, D.J. Riedel¹, E. Musabeyezu¹; ¹Office of Global Health, University of Maryland School of Nursing, Baltimore, MD, USA, ²Institute of Human Virology and Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA, ³Department of Internal Medicine, King Faisal Hospital, Kigali, Rwanda

Background: Existing research on hepatitis C virus (HCV) treatment outcomes in sub-Saharan Africa is very limited. This study was undertaken to determine the HCV sustained virologic response (SVR) 24 weeks after treatment completion and the frequency and severity of adverse events in patients undergoing HCV therapy in Kigali, Rwanda.

Methods: The study was a retrospective review study of all patients > 18 years old treated for HCV with ribavirin and interferon combination therapy at King Faisal Hospital in Kigali, Rwanda from January 1, 2007 to December 31, 2014. Patient’s paper and electronic charts were reviewed for data collection. Approval for the study was obtained from the University of Maryland Institutional Review Board and King Faisal Hospital K-Ethics and Research Committee.

Findings: The study included 69 patients; 52% were male, and the median age at the start of treatment was 48 years (range 25-69). The majority of patients had HCV Genotype 4 (61%) and <2% of patients had genotypes 1, 2, 3, or 5 (33% unknown genotype). Sustained virologic response 24 weeks following completion of treatment was 32%. 57% relapsed after six months, and 12% of patients had unknown outcomes. The most frequent side effects included headache (56%), fatigue (51%), and non-abdominal pain (49%). The most common adverse laboratory values were neutropenia (94%), thrombocytopenia (39%), and anemia (30%). Three patients (4%) died following treatment (causes of death unknown).

Interpretation: Sustained virological response of patients in this study was lower than in other studies conducted in sub-Saharan Africa. Cytopenias were the most frequent side effects and were consistent with other studies. More comprehensive studies on HCV care and treatment outcomes with the new direct acting antivirals will need to be completed as these drugs become available in Rwanda.

Funding: None.

Challenges and strategies for implementing mental health measurement for research in low-resource settings

R.L. Tennyson, C. Kemp, D. Rav; University of Washington, Seattle, USA

Background: The gap between need and access to mental health care is widest in low-resource settings. Health systems in these settings devote few resources to the expansion of mental health care, and mental health is missing from the agenda of most global health donors. This is partially explained by the paucity of data regarding the nature and extent of the burden of mental illness in these settings. The accurate and comparable measurement of this burden will be essential to advocating for, developing, and implementing appropriate policies and services for mental health in low-resource settings. This study surveys the unique challenges associated with measurement of mental health in these settings globally, and proposes a framework for use by future implementers.

Methods: We reviewed the literature on mental health measurement in low-resource settings, focusing on studies that have attempted to adapt valid, reliable assessment tools from high-resource settings and implement them in low-resource settings. We also collected case studies from researchers in the field who have direct experience in this area.